MGC Pharmaceuticals opens up European market
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceuticals (ASX:MXC) has just opened up the European market thanks to regulatory approvals.
It has received word from the European Commission’s Comestic Products Notification Portal that it has approval to start selling its cosmetic products derived from cannabidiol compounds found in cannabis in Europe.
The CPCP is the European equivalent of the US FDA or Australia’s Therapeutic Goods Association.
The approval clears the way for European consumers to start buying MXC’s goods direct – including a moisturising day cream, an anti-aging mask, and a dark circles eye serum.
It also opens the door for its European distribution partner, Czhechia-based Czech Medical Herbs to start commercialisation of the product line.
MXC has also told its shareholders that it has lodged formal applications with the US FDA and the TGA to do the same – saying that outcomes on the applications are expected “in the coming months”.
It estimates the global cosmetics market to be worth more than $460 billion.
Managing director Nativ Segev said the approval would provide a step-change for the company.
“It allows the company to commence dedicated marketing and sales efforts for its cosmetics products throughout the EU and furthering our move towards material revenue generation, as part of the large global cosmetics market,” he said.
It has previously estimated that the sales deal with Czech Medical Herbs could be worth about $500,000.
In March it unveiled a push into the pharmaceuticals R&D space, signing an agreement with Israel-based Sipnose to develop a CBD-based medicine for sufferers of epilepsy.
The retail revenue will provide a base to work from while MXC pursues a product development breakthrough, which is expected to be the main game for the company.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.